Skip to main content

Table 3 Prognostic information of CTC count and CTC clusters in a clinicopathological model

From: Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial

Model 1 Model 1 C-index Model 2 Model 2 C-index LRχ2 df P value
PFS at baselinea
 CP 0.690 CP + CTCBL 0.707 11.46 1 0.0007
 CP 0.690 CP + cluster 0.706 9.47 1 0.0021
 CP 0.690 CP + CTCBL + cluster 0.714 14.46 2 0.0007
OS at baselinea
 CP 0.752 CP + CTCBL 0.786 18.96 1 < 0.0001
 CP 0.752 CP + clusterBL 0.777 13.16 1 0.0003
 CP 0.752 CP + CTCBL + clusterBL 0.799 23.54 2 < 0.0001
PFS at 1 monthb
 CP + CTCBL 0.697 CP + CTCBL + CTC1M 0.709 6.69 1 0.0097
 CP + CTCBL 0.697 CP + CTCBL + cluster1M 0.712 7.56 1 0.0060
 CP + CTCBL 0.697 CP + CTCBL + CTC1M+cluster1M 0.713 10.56 2 0.0051
OS at 1 monthb
 CP + CTCBL 0.766 CP + CTCBL + CTC1M 0.812 15.73 1 0.0001
 CP + CTCBL 0.766 CP + CTCBL + cluster1M 0.788 12.01 1 0.0005
 CP + CTCBL 0.766 CP + CTCBL + CTC1M+cluster1M 0.817 20.57 2 < 0.0001
PFS at 3 monthsb
 CP + CTCBL 0.695 CP + CTCBL + CTC3M 0.701 7.31 1 0.0068
 CP + CTCBL 0.695 CP + CTCBL + cluster3M 0.711 6.22 1 0.0126
 CP + CTCBL 0.695 CP + CTCBL + CTC3M+cluster3M 0.710 9.01 2 0.0110
OS at 3 monthsb
 CP + CTCBL 0.774 CP + CTCBL + CTC3M 0.806 14.76 1 0.0001
 CP + CTCBL 0.774 CP + CTCBL + cluster3M 0.806 7.02 1 0.0081
 CP + CTCBL 0.774 CP + CTCBL + CTC3M+cluster3M 0.806 15.16 2 0.0005
PFS at 6 monthsb
 CP + CTCBL 0.694 CP + CTCBL + CTC6M 0.732 11.14 1 0.0008
 CP + CTCBL 0.694 CP + CTCBL + cluster6M 0.709 7.14 1 0.0075
 CP + CTCBL 0.694 CP + CTCBL + CTC6M+cluster6M 0.727 12.14 2 0.0023
OS at 6 monthsb
 CP + CTCBL 0.758 CP + CTCBL + CTC6M 0.804 15.88 1 0.0001
 CP + CTCBL 0.758 CP + CTCBL + cluster6M 0.813 13.24 1 0.0003
 CP + CTCBL 0.758 CP + CTCBL + CTC6M+cluster6M 0.818 20.66 2 < 0.0001
  1. Abbreviations: BL baseline, 3M 3 months, 6M 6 months, df degrees of freedom, LRχ2 likelihood ratio chi-square, CP clinicopathological model, CTC circulating tumor cell, PFS progression-free survival, OS overall survival
  2. aAdjusted for subtype, histologic grade, performance status (Eastern Cooperative Oncology Group (ECOG)), age, metastasis-free interval (MFI), visceral metastases, and number of metastatic locations
  3. bAdjusted for baseline CTC count ≥ 5, subtype, histologic grade, performance status (ECOG), age, MFI, visceral metastases, and number of metastatic locations. Analyses at 1, 3, and 6 months were performed by landmark analysis